Hermann Einsele

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6070945/publications.pdf

Version: 2024-02-01

134 papers	14,546 citations	36203 51 h-index	20900 115 g-index
152 all docs	152 docs citations	152 times ranked	13844 citing authors

#	Article	IF	Citations
1	Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. Biology of Blood and Marrow Transplantation, 2009, 15, 1143-1238.	2.0	1,505
2	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2015, 373, 621-631.	13.9	1,139
3	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 2021, 384, 705-716.	13.9	1,129
4	Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. New England Journal of Medicine, 2017, 377, 2433-2444.	13.9	796
5	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncology, The, 2014, 15, 1195-1206.	5.1	695
6	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 2016, 127, 2955-2962.	0.6	686
7	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	3.3	664
8	Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. Journal of Clinical Oncology, 2016, 34, 1104-1111.	0.8	359
9	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1691-1699.	5.1	347
10	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood, 2018, 132, 587-597.	0.6	335
11	The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Science Translational Medicine, 2019, 11, .	5.8	326
12	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia, 2019, 33, 159-170.	3.3	313
13	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Journal of Clinical Oncology, 2016, 34, 1544-1557.	0.8	294
14	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 2011, 117, 6063-6073.	0.6	282
15	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica, 2020, 105, 297-316.	1.7	230
16	Antiâ€“B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. Journal of Clinical Oncology, 2020, 38, 775-783.	0.8	222
17	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. Journal of Nuclear Medicine, 2016, 57, 248-251.	2.8	201
18	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	1.7	185

#	Article	IF	Citations
19	In vivo molecular imaging of chemokine receptor <scp>CXCR</scp> 4 expression in patients with advanced multiple myeloma. EMBO Molecular Medicine, 2015, 7, 477-487.	3.3	180
20	SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood, 2017, 130, 2838-2847.	0.6	164
21	Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. British Journal of Haematology, 2007, 138, 330-337.	1.2	156
22	Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. Journal of Experimental Medicine, 2016, 213, 1881-1900.	4.2	143
23	Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nature Medicine, 2021, 27, 616-619.	15.2	140
24	ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight, 2019, 4, .	2.3	139
25	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	5.1	136
26	CAR T-cells targeting FLT3 have potent activity against FLT3â˜ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia, 2018, 32, 1168-1179.	3.3	133
27	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood, 2016, 127, 713-721.	0.6	121
28	Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nature Communications, 2019, 10, 3137.	5.8	120
29	The BiTE (bispecific Tâ€cell engager) platform: Development and future potential of a targeted immunoâ€oncology therapy across tumor types. Cancer, 2020, 126, 3192-3201.	2.0	116
30	Randomized Study of Early versus Late Immunization with Pneumococcal Conjugate Vaccine after Allogeneic Stem Cell Transplantation. Clinical Infectious Diseases, 2009, 48, 1392-1401.	2.9	110
31	Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood, 2006, 107, 3002-3008.	0.6	104
32	Lowest numbers of primary CD8+ T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood, 2014, 124, 628-637.	0.6	103
33	CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. Theranostics, 2017, 7, 1589-1597.	4.6	102
34	Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. International Journal of Hematology, 2008, 88, 508-515.	0.7	94
35	Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia, 2019, 33, 447-456.	3.3	93
36	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer Journal, 2020, 10, 91.	2.8	90

#	Article	IF	Citations
37	Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Annals of Hematology, 2012, 91, 1031-1037.	0.8	82
38	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia, 2022, 36, 1371-1376.	3.3	81
39	BATF3 programs CD8+ T cell memory. Nature Immunology, 2020, 21, 1397-1407.	7.0	80
40	Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood, 2017, 129, 3386-3388.	0.6	79
41	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2021, 35, 31-44.	3.3	79
42	Inhibition of TGF-Î²-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. , 2020, 8, e000676.		75
43	Multicenter Comparison of Serum and Whole-Blood Specimens for Detection of Aspergillus DNA in High-Risk Hematological Patients. Journal of Clinical Microbiology, 2013, 51, 1445-1450.	1.8	74
44	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer Journal, 2022, 12, 32.	2.8	73
45	Cardiovascular adverse events in modern myeloma therapy â€“ Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica, 2018, 103, 1422-1432.	1.7	70
46	CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. Gene Therapy, 2021, 28, 560-571.	2.3	70
47	Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood, 2021, 137, 3145-3148.	0.6	70
48	Expert review on softâ€tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	1.2	67
49	¹¹C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. Theranostics, 2017, 7, 2956-2964.	4.6	63
50	A highly soluble Sleeping Beauty transposase improves control of gene insertion. Nature Biotechnology, 2019, 37, 1502-1512.	9.4	63
51	CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. Frontiers in Oncology, 2020, 10, 1243.	1.3	63
52	Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2019, 60, 60-64.	2.8	62
53	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	2.8	62
54	Combined realâ€time <scp>PCR</scp> and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies. British Journal of Haematology, 2013, 161, 517-524.	1.2	61

#	Article	IF	Citations
55	Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Frontiers in Immunology, 2020, 11, 762.	2.2	57
56	Interaction analyses of human monocytes co-cultured with different forms of Aspergillus fumigatus. Journal of Medical Microbiology, 2009, 58, 49-58.	0.7	50
57	Three-Dimensional Light Sheet Fluorescence Microscopy of Lungs To Dissect Local Host Immune-Aspergillus fumigatus Interactions. MBio, 2020, 11, .	1.8	49
58	Management of Cytomegalovirus Infection after Solid-Organ or Stem-Cell Transplantation. Drugs, 1998, 55, 59-72.	4.9	46
59	Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. Haematologica, 2021, 106, 1943-1956.	1.7	46
60	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. British Journal of Haematology, 2017, 178, 571-582.	1.2	45
61	CAR T cells targeting Î±_vÎ²₃integrin are effective against advanced cancer in preclinical models. Advances in Cell and Gene Therapy, 2018, 1, e11.	0.6	45
62	How to Manage Neutropenia in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 5-11.	0.2	40
63	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features. Biology of Blood and Marrow Transplantation, 2016, 22, 1988-1996.	2.0	40
64	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia, 2021, 35, 2517-2525.	3.3	40
65	Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood, 2021, 138, 1830-1842.	0.6	40
66	CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. Oncologist, 2020, 25, 112-118.	1.9	39
67	On-target restoration of a split T cell-engaging antibody for precision immunotherapy. Nature Communications, 2019, 10, 5387.	5.8	38
68	Phase <scp>II</scp> study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: <scp>DSMM XI</scp> trial. British Journal of Haematology, 2017, 179, 586-597.	1.2	30
69	Single- and double-hit events in genes encoding immune targets before and after T cellâ€“engaging antibody therapy in MM. Blood Advances, 2021, 5, 3794-3798.	2.5	30
70	The lymphoma-like polychemotherapy regimen â€œDexa-BEAMâ€•in advanced and extramedullary multiple myeloma. Annals of Hematology, 2014, 93, 1207-1214.	0.8	29
71	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. Expert Review of Hematology, 2018, 11, 219-237.	1.0	28
72	A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease. Journal of Clinical Microbiology, 2018, 56, .	1.8	28

#	Article	IF	Citations
73	Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance. Haematologica, 2018, 103, e126-e129.	1.7	28
74	Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease. Cancers, 2020, 12, 1035.	1.7	28
75	Potential influence of concomitant chemotherapy on <scp>CXCR</scp>4 expression in receptor directed endoradiotherapy. British Journal of Haematology, 2019, 184, 440-443.	1.2	25
76	Non-Invasive Imaging Provides Spatiotemporal Information on Disease Progression and Response to Therapy in a Murine Model of Multiple Myeloma. PLoS ONE, 2012, 7, e52398.	1.1	24
77	What is the future of immunotherapy in multiple myeloma?. Blood, 2020, 136, 2491-2497.	0.6	22
78	Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. Leukemia, 2022, 36, 790-800.	3.3	22
79	Human primary myeloid dendritic cells interact with the opportunistic fungal pathogenAspergillus fumigatusvia the C-type lectin receptor Dectin-1. Medical Mycology, 2017, 55, myw105.	0.3	21
80	Prospective Biomarker Screening for Diagnosis of Invasive Aspergillosis in High-Risk Pediatric Patients. Journal of Clinical Microbiology, 2017, 55, 101-109.	1.8	21
81	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica, 2019, 104, 2358-2360.	1.7	18
82	Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11. Journal of Immunotherapy, 2019, 42, 180-188.	1.2	17
83	Large Granular Lymphocyte (LGL) Expansions Comprising Oligoclonal T Cell or NK Cell Populations in Dasatinib Treated Patients Are Associated with HLA-A*0201, CMV Reactivation and Enhanced Anti-Leukemic Control.. Blood, 2009, 114, 1123-1123.	0.6	17
84	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <scp>PANORAMA</scp> 1 trial. British Journal of Haematology, 2017, 179, 66-74.	1.2	16
85	Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 561-571.	1.2	16
86	Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. Communications Biology, 2021, 4, 799.	2.0	16
87	Effect of ATGâ€F on Bâ€cell reconstitution after hematopoietic stem cell transplantation. European Journal of Haematology, 2015, 95, 514-523.	1.1	14
88	Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma. Current Opinion in Oncology, 2020, 32, 418-426.	1.1	14
89	Common Genetic Polymorphisms within NFÎºB-Related Genes and the Risk of Developing Invasive Aspergillosis. Frontiers in Microbiology, 2016, 7, 1243.	1.5	13
90	Susceptibility of A. fumigatusâ€specific Tâ€cell assays to preâ€analytic blood storage and <scp>PBMC</scp> cryopreservation greatly depends on readout platform and analytes. Mycoses, 2018, 61, 549-560.	1.8	13

#	Article	IF	Citations
91	Evaluation of Aspergillus and Mucorales specific T-cells and peripheral blood mononuclear cell cytokine signatures as biomarkers of environmental mold exposure. International Journal of Medical Microbiology, 2018, 308, 1018-1026.	1.5	13
92	⁶⁸Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms. Journal of Nuclear Medicine, 2022, 63, 96-99.	2.8	13
93	Intraâ€•and interâ€individual variability of Aspergillus fumigatus reactive Tâ€cell frequencies in healthy volunteers in dependency of mould exposure in residential and working environment. Mycoses, 2017, 60, 668-675.	1.8	12
94	Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia. Cancers, 2021, 13, 6157.	1.7	12
95	Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers. Journal of Cancer Research and Clinical Oncology, 2021, 147, 205-212.	1.2	11
96	Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. PLoS ONE, 2015, 10, e0116966.	1.1	10
97	A TNFR2-Specific TNF Fusion Protein With Improved In Vivo Activity. Frontiers in Immunology, 0, 13, .	2.2	10
98	Development of a Simple and Robust Whole Blood Assay with Dual Co-Stimulation to Quantify the Release of T-Cellular Signature Cytokines in Response to Aspergillus fumigatus Antigens. Journal of Fungi (Basel, Switzerland), 2021, 7, 462.	1.5	9
99	Salvage therapy with â€œDaraâ€KDTâ€P(A)CEâ€•in heavily pretreated, highâ€risk, proliferative, relapsed/refractory multiple myeloma. Hematological Oncology, 2022, 40, 202-211.	0.8	9
100	Junctional adhesion molecule C expression specifies a CD138low/neg multiple myeloma cell population in mice and humans. Blood Advances, 2022, 6, 2195-2206.	2.5	9
101	Human Invariant Natural Killer T cells possess immune-modulating functions duringAspergillusinfection. Medical Mycology, 2016, 54, 169-176.	0.3	8
102	Hereditary spherocytosis is associated with decreased pyruvate kinase activity due to impaired structural integrity of the red blood cell membrane. British Journal of Haematology, 2019, 187, 386-395.	1.2	8
103	Development and evaluation of a whole blood-based approach for flow cytometric quantification of CD154+ mould-reactive T cells. Medical Mycology, 2019, 58, 187-196.	0.3	7
104	Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. Annals of Hematology, 2021, 100, 1537-1546.	0.8	7
105	Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments. Communications Biology, 2021, 4, 44.	2.0	7
106	Reduced Toxicity Conditioning with Treosulfan and Fludarabine in Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: Results of an International Prospective Phase II Trial.. Blood, 2008, 112, 3274-3274.	0.6	7
107	Minimal residual disease and imagingâ€guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma. British Journal of Haematology, 2022, 198, 515-522.	1.2	7
108	Protocol for M3P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma. Methods in Molecular Biology, 2018, 1792, 117-128.	0.4	6

#	Article	IF	Citations
109	Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials. European Journal of Haematology, 2019, 103, 255-267.	1.1	6
110	Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinibâ€resistant nonâ€nodal leukemic mantle cell lymphoma. European Journal of Haematology, 2020, 104, 352-355.	1.1	6
111	Invasive fungal diseases in patients with new diagnosed acute lymphoblastic leukaemia. Mycoses, 2020, 63, 1101-1106.	1.8	6
112	Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM. Cancers, 2021, 13, 1322.	1.7	6
113	Diagnostic Performance of (1â†'3)-Î²-D-Glucan Alone and in Combination with Aspergillus PCR and Galactomannan in Serum of Pediatric Patients after Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Fungi (Basel, Switzerland), 2021, 7, 238.	1.5	6
114	Chronic Occupational Mold Exposure Drives Expansion of Aspergillus-Reactive Type 1 and Type 2 T-Helper Cell Responses. Journal of Fungi (Basel, Switzerland), 2021, 7, 698.	1.5	6
115	Treatment with etanercept and low monocyte concentration contribute to the risk of invasive aspergillosis in patients post allogeneic stem cell transplantation. Scientific Reports, 2019, 9, 17231.	1.6	5
116	A Clinical Case of COVID-19-Associated Pulmonary Aspergillosis (CAPA), Illustrating the Challenges in Diagnosis (Despite Overwhelming Mycological Evidence). Journal of Fungi (Basel, Switzerland), 2022, 8, 81.	1.5	5
117	The screening of blood by Aspergillus PCR and galactomannan ELISA precedes BAL detection in patients with proven and probable IA. Medical Mycology, 2020, 58, 856-858.	0.3	4
118	Molecular Profiling Reveals Characteristic and Decisive Signatures in Patients after Allogeneic Stem Cell Transplantation Suffering from Invasive Pulmonary Aspergillosis. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 377	1.5	4
119	Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT. Bone Marrow Transplantation, 2022, 57, 817-823.	1.3	4
120	Excretion of Ascaris lumbricoides following reducedâ€intensity allogeneic hematopoietic stem cell transplantation and consecutive treatment with mebendazole. Transplant Infectious Disease, 2020, 22, e13224.	0.7	3
121	Impact of immunosuppressive and antifungal drugs on PBMC- and whole blood-based flow cytometric CD154+ Aspergillus fumigatus specific T-cell quantification. Medical Microbiology and Immunology, 2020, 209, 579-592.	2.6	3
122	Variant signaling topology at the cancer cellâ€"T-cell interface induced by a two-component T-cell engager. Cellular and Molecular Immunology, 2021, 18, 1568-1570.	4.8	3
123	Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma. Blood Cancer Journal, 2021, 11, 51.	2.8	3
124	Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma. Oncotarget, 2016, 7, 38762-38774.	0.8	3
125	Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia. Bone Marrow Transplantation, 2022, 57, 874-880.	1.3	3
126	Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant. Leukemia and Lymphoma, 2015, 56, 3365-3369.	0.6	2

#	Article	IF	Citations
127	The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. HemaSphere, 2021, 5, e642.	1.2	2
128	COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from WÃ¼rzburg and Wuhan. Annals of Hematology, 2021, 100, 843-846.	0.8	1
129	CARTITUDE-2: Phase 2 Multicohort Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, S433-S434.	0.6	1
130	T-Cell Immune Surveillance in Allogenic Stem Cell Transplant Recipients: Are Whole Bloodâ€“Based Assays Ready to Challenge ELISPOT?. Open Forum Infectious Diseases, 2021, 8, ofaa547.	0.4	1
131	Lenalidomide, Adriamycin and Dexamethason (RAD) in Relapsed and Refractory Multiple Myeloma: Final Results from a Phase I/II Trial of â€œDeutsche Studiengruppe Multiples Myelomâ€. Blood, 2008, 112, 2782-2782.	0.6	1
132	Efficacy and Tolerability of Lenalidomide/Dexamethasone in Intensively Pretreated Myeloma Patients: Experiences from the German Named Patient Program.. Blood, 2007, 110, 4834-4834.	0.6	0
133	Real-World Experience with Minimal Residual Disease Testing with Next Generation Flow Cytometry and Functional Imaging in Multiple Myeloma. Blood, 2020, 136, 17-18.	0.6	0
134	Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. Bone Marrow Transplantation, 2022, , .	1.3	0